Cargando…
Future landscape for the management of membranous nephropathy
Among all glomerular diseases, membranous nephropathy (MN) is perhaps the one in which major progress has been made in recent decades, in both the understanding of the pathogenesis and treatment. Despite the overall significant response rates to these therapies—particularly rituximab and cyclical re...
Autores principales: | Caravaca-Fontán, Fernando, Yandian, Federico, Fervenza, Fernando C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387398/ https://www.ncbi.nlm.nih.gov/pubmed/37529655 http://dx.doi.org/10.1093/ckj/sfad041 |
Ejemplares similares
-
Targeting complement in IgA nephropathy
por: Caravaca-Fontán, Fernando, et al.
Publicado: (2023) -
Microscopic hematuria as a risk factor for IgAN progression: considering this biomarker in selecting and monitoring patients
por: Zand, Ladan, et al.
Publicado: (2023) -
PLEX in AAV-GN: insights from the meta-analysis results and impact on remission induction treatment recommendations
por: Casal Moura, Marta, et al.
Publicado: (2022) -
Membranous nephropathy: a single disease or a pattern of injury resulting from different diseases
por: Sethi, Sanjeev
Publicado: (2021) -
Oxalate nephropathy: a review
por: Rosenstock, Jordan L, et al.
Publicado: (2021)